ecteinascidin 743 has been researched along with Atypical Lipomatous Tumor in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (5.41) | 29.6817 |
| 2010's | 22 (59.46) | 24.3611 |
| 2020's | 13 (35.14) | 2.80 |
| Authors | Studies |
|---|---|
| Grimison, P; King, D; Thomson, K; Zhou, DD | 1 |
| Aicher, L; Black, G; Cranmer, LD; He, Q; Hermida de Viveiros, P; Johnson, R; Jones, RL; Loggers, ET; Maxwell, S; McDonnell, S; Moore, R; Pollack, SM; Smythe, KS; Wagner, MJ; Zhang, Y | 1 |
| Schöffski, P | 1 |
| Amini, B; Araujo, D; Benjamin, RS; Cloutier, JM; Conley, AP; Feig, B; Keung, EZ; Lin, H; Livingston, JA; Ludwig, J; Nassif, EF; Patel, S; Ratan, R; Ravi, V; Roland, CL; Somaiah, N; Thirasastr, P; Wang, WL; Zarzour, MA; Zhou, X | 1 |
| Grignani, G; Hindi, N; Ibrahim, T; Le Cesne, A; Martín-Broto, J; Merlini, A | 1 |
| Aquilano, M; Becherini, C; Campanacci, DA; Francolini, G; Greto, D; Livi, L; Loi, M; Mangoni, M; Melica, ME; Salvatore, G; Salvestrini, V; Santini, C; Sottili, M; Talamonti, C; Valzano, M | 1 |
| Adachi, Y; Akiyama, T; Iwata, S; Kawai, A; Kojima, N; Kondo, T; Noguchi, R; Ohtori, S; Ono, T; Osaki, J; Sato, C; Sin, Y; Tsuchiya, R; Yoshida, A; Yoshimatsu, Y | 1 |
| Assi, T; Bahleda, R; Faron, M; Hénon, C; Honoré, C; Le Cesne, A; Le Péchoux, C; Lévy, A; Ngo, C; Verret, B | 1 |
| Blay, JY | 1 |
| Itonaga, I; Iwasaki, T; Kawano, M; Matsuda, S; Tanaka, K; Tsumura, H | 1 |
| Almond, M; Beggs, A; Desai, A; Ford, S; Taniere, P; Tyler, R; Wanigasooriya, K | 1 |
| Blay, JY; de Sande González, LM; Kasper, B; Le Cesne, A; Martin-Broto, J | 1 |
| Hirabayashi, K; Kikuta, K; Kondo, T; Noguchi, R; Ono, T; Ozawa, I; Sei, A; Yoshimatsu, Y | 1 |
| Schuetze, S | 1 |
| Allonca, E; Astudillo, A; Fernandez-Garcia, MT; Garcia-Pedrero, JM; Martinez-Cruzado, L; Rodriguez, A; Rodriguez, R; Santos, L; Tornin, J | 1 |
| Bello, E; Capasso Palmiero, U; D'Incalci, M; De Maglie, M; Ferrari, M; Frapolli, R; Matteo, C; Minoli, L; Morbidelli, M; Morosi, L; Moscatelli, D; Ponzo, M; Romanelli, P; Zucchetti, M | 1 |
| Amoreo, CA; Biagini, R; Bon, G; Covello, R; D'Incalci, M; Del Bufalo, D; Falcioni, R; Ferraresi, V; Frapolli, R; Laquintana, V; Loria, R; Milella, M; Novello, M; Trisciuoglio, D; Zoccali, C | 1 |
| Demetri, GD; Elias, A; Hamm, J; Hensley, ML; Jones, RL; Knoblauch, R; Maki, RG; McCarthy, S; Milhem, M; Parekh, T; Patel, S; Schuetze, SM; Van Tine, BA; von Mehren, M; Wang, G | 1 |
| Dry, SM; Eilber, FC; Elliott, I; Hoffman, RM; Igarashi, K; Kanaya, F; Kawaguchi, K; Kiyuna, T; Li, Y; Miyake, K; Miyake, M; Murakami, T; Nelson, SD; Russell, TA; Singh, AS; Singh, SR; Tome, Y | 1 |
| Merimsky, O; Shamai, S | 1 |
| Amano, K; Chika, N; Fukuchi, M; Hatano, S; Ishibashi, K; Ishida, H; Ishiguro, T; Ito, T; Kumagai, Y; Mochiki, E; Muramatsu, S; Muta, Y; Suzuki, O; Toyomasu, Y | 1 |
| Baldi, GG; Gronchi, A; Suarez-Kelly, LP | 1 |
| Cornillie, J; Debiec-Rychter, M; Hompes, D; Langmans, C; Schöffski, P; Sciot, R; van Cann, T; Vandenbempt, I; Wozniak, A | 1 |
| Charlson, J; Chawla, SP; D'Amato, G; Demetri, GD; Forscher, C; Hensley, ML; Kaiser, P; Knoblauch, R; Livingston, M; Maki, RG; McCarthy, S; Parekh, T; Patel, S; Reed, DR; Rushing, D; Ryan, CW; Seth, R; Singh, A; von Mehren, M; Wang, G | 1 |
| Ahrens, M; Bauer, S; Grabellus, F; Hoiczyk, M; Podleska, L; Pöttgen, C; Schuler, M; Schwindenhammer, B; Taeger, G | 1 |
| Albano, A; Guida, M; Lorusso, V; Strippoli, S | 1 |
| Blay, JY; Casali, P; Le Cesne, A; Nieto, A; Tanović, A | 1 |
| Elowsson, C; Krarup-Hansen, A; Mouritsen, LS; Safwat, A; Schack, LH | 1 |
| Hohenberger, P; Kasper, B; Mathew, M; Pink, D; Rauch, G; Reichardt, P; Sommer, M | 1 |
| Dean, A; Demetri, GD; Elias, A; Ganjoo, K; Hensley, ML; Jones, RL; Khokhar, NZ; Knoblauch, RE; Maki, RG; Milhem, M; Parekh, TV; Park, YC; Patel, SR; Schuetze, SM; Spira, A; Staddon, A; Tawbi, H; Van Tine, BA; von Mehren, M | 1 |
| Balzarini, L; Bastoni, S; Bertuzzi, AF; Daolio, P; De Sanctis, R; Lutman, FR; Marchetti, S; Marrari, A; Mussi, C; Quagliuolo, V; Santoro, A | 1 |
| Gronchi, A; Saponara, M; Stacchiotti, S | 1 |
| von Mehren, M; Zijoo, R | 1 |
| Blay, JY; Buckley, B; Elsayed, YA; Fanucchi, MP; Gilles, L; Le Cesne, A; Lebedinsky, C; Ray-Coquard, I; Samuels, BL; von Mehren, M | 1 |
| Baker, LH; Blay, JY; Chawla, SP; Demetri, GD; Elsayed, YA; Gómez, J; Hande, KR; Izquierdo, MA; Keohan, ML; Le Cesne, A; Lebedinsky, C; Park, YC; Ritch, P; Samuels, BL; Schuetze, S; von Mehren, M | 1 |
| Bui-Nguyen, B; Italiano, A; Toulmonde, M | 1 |
| Etienne-Grimaldi, MC; Fernandez-Teruel, C; Gastaud, L; Ghafari, T; Launay-Vacher, V; Marcy, PY; Milano, G; Renée, N; Soto-Matos, A; Thariat, J; Thyss, A | 1 |
8 review(s) available for ecteinascidin 743 and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Topics: Doxorubicin; Humans; Ifosfamide; Liposarcoma; Sarcoma; Trabectedin | 2022 |
Systemic Therapy in Advanced Pleomorphic Liposarcoma: a Comprehensive Review.
Topics: Doxorubicin; Humans; Liposarcoma; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2023 |
A review of retroperitoneal liposarcoma genomics.
Topics: Animals; Antineoplastic Agents, Alkylating; Chromosome Aberrations; Genomics; Humans; Liposarcoma; Oncogene Proteins, Fusion; Phosphatidylinositol 3-Kinases; Retroperitoneal Neoplasms; Trabectedin | 2020 |
Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma.
Topics: Antineoplastic Agents, Alkylating; Humans; Leiomyosarcoma; Liposarcoma; Quality of Life; Randomized Controlled Trials as Topic; Sarcoma; Trabectedin | 2020 |
Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Drug Discovery; Drugs, Investigational; Furans; Humans; Ketones; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2019 |
The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.
Topics: Algorithms; Antineoplastic Agents, Alkylating; Dioxoles; Drug Design; Humans; Leiomyosarcoma; Liposarcoma; Prognosis; Tetrahydroisoquinolines; Time Factors; Trabectedin | 2016 |
Efficacy of trabectedin for the treatment of liposarcoma.
Topics: Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Liposarcoma; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2016 |
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2010 |
8 trial(s) available for ecteinascidin 743 and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
A Phase 1/2 Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; B7-H1 Antigen; Humans; Leiomyosarcoma; Leukocytes, Mononuclear; Liposarcoma; Trabectedin | 2022 |
Efficacy and tolerability of trabectedin in elderly patients with sarcoma: subgroup analysis from a phase III, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Topics: Administration, Intravenous; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Progression-Free Survival; Time Factors; Trabectedin; Young Adult | 2018 |
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Survival Analysis; Trabectedin | 2019 |
Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dioxoles; Drug Administration Schedule; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2014 |
Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Deoxycytidine; Dioxoles; Drug Therapy, Combination; Female; Gemcitabine; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Thrombocytopenia; Trabectedin; Transaminases | 2015 |
Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2016 |
Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Disease-Free Survival; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leiomyosarcoma; Liposarcoma; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Sarcoma; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2008 |
Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Australia; Dioxoles; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Europe; Female; Humans; Ifosfamide; Infusions, Intravenous; Kaplan-Meier Estimate; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Staging; North America; Proportional Hazards Models; Risk Assessment; Tetrahydroisoquinolines; Time Factors; Trabectedin; Treatment Failure; Young Adult | 2009 |
21 other study(ies) available for ecteinascidin 743 and Atypical Lipomatous Tumor
| Article | Year |
|---|---|
Trabectedin for metastatic liposarcoma and leiomyosarcoma: Comparison of real-world experience in an Australian sarcoma specialist center to pivotal clinical trial results.
Topics: Antineoplastic Agents, Alkylating; Australia; Clinical Trials as Topic; Humans; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin | 2022 |
Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma.
Topics: Adult; Aged; Aged, 80 and over; Docetaxel; Gemcitabine; Humans; Liposarcoma; Middle Aged; Retrospective Studies; Trabectedin | 2023 |
Experience with second-line trabectedin in daily clinical practice: case studies.
Topics: Adult; Antineoplastic Agents, Alkylating; Dioxoles; Female; Humans; Liposarcoma; Male; Neoplasm Recurrence, Local; Quality of Life; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2022 |
Radiosensitizing Effect of Trabectedin on Human Soft Tissue Sarcoma Cells.
Topics: Antineoplastic Agents, Alkylating; Fibrosarcoma; Humans; Leiomyosarcoma; Liposarcoma; Radiation-Sensitizing Agents; Rhabdomyosarcoma; Sarcoma; Soft Tissue Neoplasms; Trabectedin; Tumor Microenvironment | 2022 |
Establishment and characterization of NCC-PLPS2-C1: a novel cell line of pleomorphic liposarcoma.
Topics: Antineoplastic Agents; Cell Line, Tumor; Humans; Liposarcoma; Trabectedin | 2023 |
Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Furans; Gemcitabine; Humans; Ifosfamide; Indazoles; Ketones; Liposarcoma; Middle Aged; Prognosis; Pyrimidines; Sulfonamides; Survival Rate; Trabectedin | 2019 |
Long-term disease control by trabectedin in a patient with dedifferentiated liposarcoma: A case report.
Topics: Aged; Antineoplastic Agents, Alkylating; Humans; Liposarcoma; Male; Neoplasm Metastasis; Trabectedin | 2020 |
Establishment and characterization of a novel cell line, NCC-DDLPS2-C1, derived from a patient with dedifferentiated liposarcoma.
Topics: Aged, 80 and over; Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Chromosomes, Human, Pair 12; Depsipeptides; Female; Gene Dosage; Humans; Karyotype; Liposarcoma; Neoplasm Invasiveness; Spheroids, Cellular; Trabectedin | 2021 |
Trabectedin: useful in leiomyosarcoma and liposarcoma, but less so in other soft tissue sarcomas.
Topics: Humans; Leiomyosarcoma; Liposarcoma; Sarcoma; Trabectedin | 2021 |
Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Cycle Checkpoints; Cell Proliferation; Dioxoles; DNA Damage; Drug Synergism; Humans; Liposarcoma; Liposarcoma, Myxoid; Mice; Neoplastic Stem Cells; Signal Transduction; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2017 |
Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin.
Topics: Animals; Antineoplastic Agents, Alkylating; Female; Liposarcoma; Mice, Inbred C57BL; Mice, Nude; Nanoparticles; Polymers; Skin; Solubility; Tissue Distribution; Trabectedin; Water | 2018 |
HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance.
Topics: Antineoplastic Agents, Alkylating; Disease Progression; Drug Resistance, Neoplasm; E2F1 Transcription Factor; HMGA Proteins; Humans; Liposarcoma; NF-kappa B; Signal Transduction; Trabectedin | 2018 |
Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Resistance, Neoplasm; Humans; Liposarcoma; Male; Mice; Neoplasm Recurrence, Local; Receptor, Platelet-Derived Growth Factor alpha; Tetrahydroisoquinolines; Trabectedin; Xenograft Model Antitumor Assays | 2018 |
Trabectedin for Advanced Soft Tissue Sarcoma: Ten Year Real-Life Perspective.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Cohort Studies; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Retrospective Studies; Sarcoma; Survival Rate; Trabectedin; Young Adult | 2018 |
[A Case of Giant Retroperitoneal Liposarcoma Resected after Trabectedin Chemotherapy].
Topics: Antineoplastic Agents, Alkylating; Humans; Liposarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Retroperitoneal Neoplasms; Trabectedin | 2018 |
Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Doxorubicin; Female; Humans; Ifosfamide; Liposarcoma; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Tertiary Care Centers; Trabectedin; Treatment Outcome; Young Adult | 2019 |
Trabectedin in metastatic soft tissue sarcomas: Role of pretreatment and age.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Dioxoles; Disease Progression; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Sarcoma; Tetrahydroisoquinolines; Trabectedin | 2013 |
Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin.
Topics: Dioxoles; Herb-Drug Interactions; Humans; Liposarcoma; Male; Middle Aged; Photinia; Plant Extracts; Rhabdomyolysis; Tetrahydroisoquinolines; Trabectedin | 2013 |
The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Chondrosarcoma; Denmark; Dioxoles; Female; Humans; Hyponatremia; Karnofsky Performance Status; Leiomyosarcoma; Liposarcoma; Middle Aged; Multivariate Analysis; Retrospective Studies; Sarcoma; Tetrahydroisoquinolines; Trabectedin; Young Adult | 2015 |
Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dioxoles; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Sarcoma; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome; Young Adult | 2015 |
Pharmacokinetics of trabectedin on hemodialysis: an application for the management of cancer patients with end-stage renal disease.
Topics: Antineoplastic Agents, Alkylating; Area Under Curve; Dioxoles; Female; Half-Life; Humans; Kidney Failure, Chronic; Liposarcoma; Middle Aged; Renal Dialysis; Tetrahydroisoquinolines; Trabectedin | 2011 |